Cancer cells, including glioblastoma (GBM) tumor cells that are highly resistant to all known therapies, express tumor-specific receptors, IL-13RA2 and EphA2 (these receptors are not present in normal cells). The breakthrough of WPD Pharmaceuticals’ solution will be based on the use of therapy targeting IL-13RA2 and EphA2 receptors by genetically modified IL-13 and Ephrin 1 proteins, conjugated to Pseudomonas and Diphtheria bacteria toxins.
Read More
Berubicin is an exciting new drug that is one of the first anthracyclines proven to cross the blood-brain barrier (BBB) and able to reach brain tumors. This discovery can potentially extend the clinical use of anthracyclines to brain tumors, specifically GBM.
Read More
WP1066 represents a new class of drugs, which WPD calls “Immune/Transcription Modulators”. WP1066 and related analogs have not only demonstrated the ability to directly induce apoptosis (tumor cell death) but also the ability to stimulate an immune response to tumors allowing T-cells to attack tumor cells. These unique drug properties are a result of WP1066’s ability to inhibit the activated form of STAT3, (p-STAT3).
Read More